<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04272567</url>
  </required_header>
  <id_info>
    <org_study_id>Yi Chen-2020-1</org_study_id>
    <nct_id>NCT04272567</nct_id>
  </id_info>
  <brief_title>Norepinephrine Prophylaxis for Postspinal Anesthesia Hypotension</brief_title>
  <official_title>Norepinephrine Prophylaxis for Postspinal Anesthesia Hypotension in Parturients Undergoing Cesarean Section: a Randomized, Placebo-controlled Dose-finding Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Ningxia Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Ningxia Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the suitable infusion dose of norepinephrine for
      prophylaxis against post-spinal anesthesia hypotension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-spinal anesthesia hypotension is a frequent complication during spinal anesthesia for
      cesarean section. The incidence of post-spinal anesthesia hypotension is as high as
      62.1-89.7% if prophylactic measures are not taken. Vasopressors has been highly recommended
      for routine prevention and/or treatment of post-spinal anesthesia hypotension. As a potential
      substitute drug for phenylephrine, norepinephrine has gradually been used in parturients
      undergoing cesarean section. There's some evidence that prophylactic infusion of
      norepinephrine could effectively reduce the incidence of post-spinal anesthesia hypotension
      in parturients undergoing cesarean section. But the ideal infusion dose of norepinephrine is
      still unknown. The purpose of this study is to investigate the suitable infusion dose of
      norepinephrine for prophylaxis against post-spinal anesthesia hypotension.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 28, 2020</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of post-spinal anesthesia hypotension</measure>
    <time_frame>1-15 minutes after spinal anesthesia.</time_frame>
    <description>Systolic blood pressure (SBP) &lt; 80% of the baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall stability of systolic blood pressure control versus baseline</measure>
    <time_frame>1-15 minutes after spinal anesthesia.</time_frame>
    <description>Evaluated by performance error (PE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall stability of heart rate control versus baseline</measure>
    <time_frame>1-15 minutes after spinal anesthesia.</time_frame>
    <description>Evaluated by performance error (PE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of severe post-spinal anesthesia hypotension.</measure>
    <time_frame>1-15 minutes after spinal anesthesia.</time_frame>
    <description>Systolic blood pressure (SBP) &lt; 60% of the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of nausea and vomiting.</measure>
    <time_frame>1-15 minutes after spinal anesthesia.</time_frame>
    <description>Presence of nausea and vomiting in patients after spinal anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of bradycardia.</measure>
    <time_frame>1-15 minutes after spinal anesthesia.</time_frame>
    <description>Heart rate &lt; 55 beats/min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of hypertension.</measure>
    <time_frame>1-15 minutes after spinal anesthesia.</time_frame>
    <description>Systolic blood pressure (SBP) &gt;120% of the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH</measure>
    <time_frame>Immediately after delivery.</time_frame>
    <description>From umbilical vein blood gases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial pressure of oxygen</measure>
    <time_frame>Immediately after delivery.</time_frame>
    <description>From umbilical vein blood gases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Base excess</measure>
    <time_frame>Immediately after delivery.</time_frame>
    <description>From umbilical vein blood gases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APGAR score</measure>
    <time_frame>1min after delivery</time_frame>
    <description>A= Appearance P=Pulse G=Grimace A=Attitude R=Respiration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APGAR score</measure>
    <time_frame>5min after delivery</time_frame>
    <description>A= Appearance P=Pulse G=Grimace A=Attitude R=Respiration</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Adverse Effect</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Simultaneous with subarachnoid block, a bolus of 1ml normal saline was given followed by normal saline infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.025 μg/kg/min group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.025 μg/kg/min).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.05 μg/kg/min group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.05 μg/kg/min).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.075 μg/kg/min group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.075 μg/kg/min).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1 μg/kg/min group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.1 μg/kg/min).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by different infusion dose of norepinephrine.</description>
    <arm_group_label>0.025 μg/kg/min group</arm_group_label>
    <arm_group_label>0.05 μg/kg/min group</arm_group_label>
    <arm_group_label>0.075 μg/kg/min group</arm_group_label>
    <arm_group_label>0.1 μg/kg/min group</arm_group_label>
    <other_name>Vasopressors</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Simultaneous with subarachnoid block, a bolus of 1ml normal saline was given followed by normal saline infusion</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>NS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-40 years

          -  Primipara or multipara

          -  Singleton pregnancy ≥37 weeks

          -  American Society of Anesthesiologists physical status classification I to II

          -  Scheduled for elective cesarean section under spinal anesthesia

        Exclusion Criteria:

          -  Body height &lt; 150 cm

          -  Body weight &gt; 100 kg or body mass index (BMI) ≥ 40 kg/m2

          -  Eclampsia or chronic hypertension or baseline blood pressure ≥ 160mmHg

          -  Hemoglobin &lt; 7g/dl

          -  Fetal distress, or known fetal developmental anomaly
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xinli Ni, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>General Hospital of Ningxia Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Hospital of Ningxia Medical University</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <zip>750004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 11, 2020</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Norepinephrine</keyword>
  <keyword>Hypotension</keyword>
  <keyword>Cesarean section</keyword>
  <keyword>Dose-finding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

